Genprex, Inc. filings document regulatory disclosures for a Nasdaq-listed clinical-stage gene therapy company with common stock traded on The Nasdaq Capital Market under GNPX. The company’s 8-K reports record material-event disclosures on Reqorsa patent grants and patent-application actions, research agreements, investor presentations, preclinical and clinical data presentations, diabetes gene therapy updates, and Nasdaq listing-compliance matters.
Proxy materials provide governance and compensation disclosures, including director and executive compensation tables, pay-versus-performance information and annual meeting matters. The filing record also ties Genprex’s capital-market status to its common stock listing, minimum stockholders’ equity compliance, and Regulation FD treatment for furnished presentation materials and press-release exhibits.
Genprex, Inc. filed an 8-K describing new investor presentation materials and important updates on its GPX-002 diabetes gene therapy program. The company furnished an investor deck that may be used in meetings with investors and analysts and made available on its website.
Genprex reported 2025 milestones for GPX-002, including starting preclinical research in Type 2 diabetes animal models, transferring production of GPX-002 to an experienced contract development and manufacturing organization, and submitting a request to the FDA for a meeting on its Investigational New Drug–enabling studies, described as a pivotal step toward human clinical trials. GPX-002 is being developed for both Type 1 and Type 2 diabetes, with preclinical mouse and non-human primate data showing restored or improved blood glucose control, reduced insulin requirements, higher c‑peptide levels, and improved glucose tolerance.
Genprex, Inc. reported that its Chief Medical Officer received an award of 28,500 restricted stock units (RSUs) of common stock on 12/22/2025. The RSUs were granted at a price of $0 per share under the company’s 2018 Equity Incentive Plan, as amended and restated effective June 30, 2025.
The award vests in two equal installments of 50% on February 27, 2026 and 50% on February 27, 2027, conditioned on continued service through each vesting date. Once vested, each RSU will be settled in one share of Genprex common stock. After this grant and giving effect to a 1-for-50 reverse stock split of Genprex’s common stock that was effective as of October 21, 2025, the reporting officer beneficially owns 28,860 shares of common stock.
Genprex, Inc. reported that its President, CEO and CFO, Ryan Confer, received an award of 45,000 restricted stock units (RSUs) of common stock on December 22, 2025 under the company’s 2018 Equity Incentive Plan. These RSUs vest in two equal installments of 50% on February 27, 2026 and 50% on February 27, 2027, if he continues to serve as a service provider through each vesting date. Each vested RSU will be settled in one share of Genprex common stock. Following this grant and giving effect to Genprex’s 1-for-50 reverse stock split effective as of October 21, 2025, Confer beneficially owns 45,661 shares of Genprex common stock in total.
Genprex, Inc. director Brent Longnecker reported receiving an award of 9,000 Restricted Stock Units (RSUs) of Genprex common stock on 12/22/2025 under the company’s 2018 Equity Incentive Plan. These RSUs vest 100% on the earlier of August 15, 2026 or the day before Genprex’s next annual stockholder meeting after the grant date, as long as he continues to serve as a service provider through that date. Each vested RSU will be settled in one share of Genprex common stock.
After this grant and giving effect to Genprex’s 1-for-50 reverse stock split effective as of October 21, 2025, Longnecker beneficially owns 9,165 shares of common stock directly and 10 shares indirectly through Longnecker Associates Ltd.
Genprex, Inc. filed an amended Form S-1 to register up to 1,280,088 shares of common stock for resale by existing investors, all issuable upon exercise of outstanding warrants. These are secondary sales, so any proceeds from selling the registered shares will go to the selling stockholders; Genprex would only receive cash if the warrants are exercised.
Genprex is a clinical-stage gene therapy company developing its lead oncology candidate REQORSA for non-small cell and small cell lung cancer in the Acclaim-1 and Acclaim-3 Phase 1/2 programs, both of which have FDA Fast Track status and, for Acclaim-3, Orphan Drug Designation. The company is also advancing GPX-002, a diabetes gene therapy licensed from the University of Pittsburgh, through preclinical work and new sponsored research.
Recent corporate actions include a 1-for-50 reverse stock split, October 2025 registered direct offerings with concurrent private warrants, an equity line of credit with Lincoln Park, and ongoing ATM sales to raise capital. As of November 19, 2025, Genprex had 2,318,894 shares outstanding and remains listed on Nasdaq under “GNPX,” with a panel-granted exception until December 31, 2025 to demonstrate long-term compliance with the stockholders’ equity requirement.
Genprex, Inc. reports that a Nasdaq Hearings Panel has determined the company has regained compliance with Nasdaq’s $1.00 minimum bid price requirement. The Panel also approved an exception giving Genprex until December 31, 2025 to demonstrate long-term compliance with the Nasdaq stockholders’ equity requirement, with the possibility of further extension to February 9, 2026 at the Panel’s discretion.
The Panel may reconsider this exception if new events make continued listing inadvisable, and there is no assurance of any extension beyond December 31, 2025. Genprex states it believes it will need to complete additional capital raising transactions to regain compliance with the stockholders’ equity requirement, and notes there is no guarantee such financing will be available on acceptable terms, or at all.
Genprex, Inc. has filed an S-1 registering the resale of up to 1,280,088 shares of common stock issuable upon exercise of outstanding warrants by selling stockholders. The company’s common stock outstanding was 2,318,894 shares as of November 19, 2025, and would be 3,598,982 shares if all registered warrants are exercised. Genprex will not receive any proceeds from stockholder resales, but will receive cash only if the warrants are exercised.
Genprex is a clinical-stage gene therapy company developing its REQORSA oncology platform for non-small cell and small cell lung cancer, where key trials have FDA Fast Track and Orphan Drug designations, and a diabetes gene therapy program licensed from the University of Pittsburgh. Recent financing steps include a 1-for-50 reverse stock split, October 2025 registered direct offerings with accompanying private warrants, a $12.5 million equity line of credit, and sales under an ATM facility to support ongoing trials and preclinical work.
Genprex, Inc. filed a prospectus supplement for an at-the-market offering of additional common stock with an aggregate offering price of up to $75,000,000 under its existing agreement with H.C. Wainwright & Co., LLC.
This supplement updates the prior ATM prospectus documents and must be read together with them. Genprex has previously sold 796,065 shares of common stock for aggregate gross proceeds of $14,796,375 under the same Sales Agreement. A legal opinion from Lowenstein Sandler LLP covering the validity of the newly registered shares is included as an exhibit.
Genprex, Inc. is registering the offer and sale of up to $75,000,000 of additional common stock under an at-the-market offering agreement with H.C. Wainwright & Co. This prospectus supplement updates prior prospectuses and reflects a one-for-fifty reverse stock split of Genprex’s common stock effective October 21, 2025. The company’s common stock trades on the Nasdaq Capital Market under the symbol GNPX, and the last reported sale price on November 21, 2025 was $3.00 per share. The securities are described as involving a high degree of risk, with detailed risk factors incorporated by reference.
Genprex, Inc. reported that it has added Gabrail Cancer Center in Canton, Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 studies of lead drug candidate REQORSA Gene Therapy in lung cancer. The company also plans to add and open additional Acclaim trial sites over the coming months to reach more patients and speed enrollment.
Acclaim-1 is a Phase 1/2 trial in late-stage non-small cell lung cancer with EGFR mutations combining REQORSA with Tagrisso, with a Phase 2a expansion targeting about 33 patients and an interim analysis after 19 patients, which Genprex currently expects to fully enroll in the first half of 2026; the trial has FDA Fast Track Designation. Acclaim-3 is a Phase 1/2 trial in extensive stage small cell lung cancer combining REQORSA with Tecentriq as maintenance therapy, with Phase 2 expansion for about 50 patients and an interim analysis after the 25th patient reaches 18 weeks of follow-up, also expected to reach that enrollment milestone in the first half of 2026, and benefits from FDA Fast Track and Orphan Drug Designations.